Xabier Garcia-Albeniz, Anja Rudolph, Carolyn Hutter, Emily White, Yi Lin, Stephanie A Rosse, Jane C Figueiredo, Tabitha A Harrison, Shuo Jiao, Hermann Brenner, Graham Casey, Thomas J Hudson, Mark Thornquist, Loic Le Marchand, John Potter, Martha L Slattery, Brent Zanke, John A Baron, Bette J Caan, Stephen J Chanock, Sonja I Berndt, Deanna Stelling, Charles S Fuchs, Michael Hoffmeister, Katja Butterbach, Mengmeng Du, W James Gauderman, Marc J Gunter, Mathieu Lemire, Shuji Ogino, Jennifer Lin, Richard B Hayes, Robert W Haile, Robert E Schoen, Greg S Warnick, Mark A Jenkins, Stephen N Thibodeau, Fredrick R Schumacher, Noralane M Lindor, Laurence N Kolonel, John L Hopper, Jian Gong, Daniela Seminara, Bethann M Pflugeisen, Cornelia M Ulrich, Conghui Qu, David Duggan, Michelle Cotterchio, Peter T Campbell, Christopher S Carlson, Polly A Newcomb, Edward Giovannucci, Li Hsu, Andrew T Chan, Ulrike Peters, Jenny Chang-Claude
BACKGROUND: Menopausal hormone therapy (MHT) use has been consistently associated with a decreased risk of colorectal cancer (CRC) in women. Our aim was to use a genome-wide gene-environment interaction analysis to identify genetic modifiers of CRC risk associated with use of MHT. METHODS: We included 10 835 postmenopausal women (5419 cases and 5416 controls) from 10 studies. We evaluated use of any MHT, oestrogen-only (E-only) and combined oestrogen-progestogen (E+P) hormone preparations...
January 19, 2016: British Journal of Cancer